VPTDF - Ventripoint Issues Option Grants and Reports Exercise of Options and Warrants
(TheNewswire)
Toronto, Ontario – TheNewswire– January 21, 2022 - VentripointDiagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”)(TSXV:VPT ) , ( OTC:VPTDF) announces that on January20, 2022 the Corporation granted an aggregate of 1,725,000 options todirectors, officers, employees, contractors and consultants of theCorporation with an exercise price of $0.40 and with terms from one toten years and vesting from immediately to over 3 years. Of theseoption grants, 500,000 were awarded to directors and officers of theCorporation. The Corporation now has 4,096,590 options available forfuture grants under the Stock Option Plan as approved by shareholdersat the last Special and Annual General Meeting on August 9,2021.
Since the last update (see NR May 6, 2021), a total of 1,770,000 options were exercised witha weighted average price of approximately $0.22 per share for grossproceeds to the Corporation of $385,250. There are currently8,958,750 option grants outstanding with exercise prices between $0.10to $0.50 with a weighted average price of $0.27, and 5,037,500 ofthese options have vested.
Since the last update (see NR May 6, 2021), the Corporation has had 1,000,000 of thewarrants issued on October 2, 2019 exercised at the strike price of$0.115 for gross proceeds of $115,000. There remain 288,666outstanding warrants in this series, which expire on October 2, 2022.
The Corporation currently has 155,558,905 commonshares issued and outstanding.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in theapplication of AI (Artificial Intelligence) to echocardiography.Ventripoint's VMS products are powered by its proprietary KBRtechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI.This affordable, gold-standard alternative allows cardiologistsgreater confidence in the management of their patients. Providingbetter care to patients serves as a springboard and basic standard forall of Ventripoint's products that guide our future developments. Inaddition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe and Canada.
For further information, please contact:
Peter Weichler, Investor Relations
Email: peter@weichler.ca
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Corporation . Although the Corporation believes that theexpectations and assumptions on which such forward-looking statementsand information are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because the Corporation can give noassurance that they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Corporation 's most recent annualmanagement's discussion and analysis that is available on the Corporation 's profile onSEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Corporation undertakes no obligation to update publicly or revise anyforward-looking statements or information, whether as a result of newinformation, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.